An open label, randomized phase 2 trial assessing the impact of food on the tolerability of abemaciclib in patients with advanced breast cancer.
Saved in:
| Title: | An open label, randomized phase 2 trial assessing the impact of food on the tolerability of abemaciclib in patients with advanced breast cancer. |
|---|---|
| Authors: | Lim E; Garvan Institute of Medical Research, St. Vincent's Clinical School, University of New South Wales, 370 Victoria Street, Darlinghurst, NSW, Australia. e.lim@garvan.org.au., Boyle F; Mater Hospital, North Sydney, NSW, Australia., Okera M; Adelaide Cancer Centre, Kurralta Park, SA, Australia., Loi S; Peter MacCallum Cancer Centre, Melbourne, VI, Australia., Goksu SS; Akdeniz University Medical Faculty, Antalya, Turkey., van Hal G; Eli Lilly and Company, Utrecht, Netherlands., Chapman SC; Eli Lilly and Company, Windlesham, Surrey, UK., Gable JC; Eli Lilly and Company, Indianapolis, IN, USA., Chen Y; Eli Lilly and Company, Indianapolis, IN, USA., Price GL; Eli Lilly and Company, Indianapolis, IN, USA., Hossain AM; Eli Lilly and Company, Indianapolis, IN, USA., Gainford MC; Eli Lilly and Company, Indianapolis, IN, USA., Ezquerra MB; Hospital Universitario Vall d'Hebron and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. |
| Source: | Breast cancer research and treatment [Breast Cancer Res Treat] 2022 Oct; Vol. 195 (3), pp. 275-287. Date of Electronic Publication: 2022 Aug 01. |
| Publication Type: | Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial |
| Journal Info: | Publisher: Kluwer Academic Country of Publication: Netherlands NLM ID: 8111104 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7217 (Electronic) Linking ISSN: 01676806 NLM ISO Abbreviation: Breast Cancer Res Treat Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1573-7217 |
|---|---|
| DOI: | 10.1007/s10549-022-06690-5 |
